[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-367695-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-367695-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","analysis-of-the-optimal-patterns-of-serum-alpha-fetoprotein-afp-afp-l3-and-protein-induced-by-vitamin-k-absence-or-antagonist-ii-pivka-ii-detection-in-the-diagnosis-of-liver-cancers","Analysis of the Optimal Patterns of Serum Alpha Fetoprotein (AFP), AFP-L3% and Protein Induced by Vitamin K Absence or Antagonist-II (PIVKA-II) Detection in the Diagnosis of Liver Cancers","","Background: Liver cancers are common malignancies mainly including hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA). Serum tumor markers for HCC commonly include AFP, AFP-L3% and PIVKA-II, while CCA often uses CEA and CA19-9. Despite many HCC diagnostic models combining AFP, AFP-L3% and PIVKA-II, guidance is limited on selecting markers and combinations. Methods: Serum tumor marker data were collected from HCC, CCA and benign liver disease cohorts and evaluated using published models. Results: Marker levels and model performance differed across cohorts, identifying top-performing models by cancer stage. Conclusions: Combined-marker diagnostic models improved efficacy, with selected models showing preference for clinical use in HCC, overall, and early liver cancers.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/analysis-of-the-optimal-patterns-of-serum-alpha-fetoprotein-afp-afp-l3-and-protein-induced-by-vitamin-k-absence-or-antagonist-ii-pivka-ii-detection-in-the-diagnosis-of-liver-cancers/367695/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/analysis-of-the-optimal-patterns-of-serum-alpha-fetoprotein-afp-afp-l3-and-protein-induced-by-vitamin-k-absence-or-antagonist-ii-pivka-ii-detection-in-the-diagnosis-of-liver-cancers/367695.png","ImageObject",300,407,{"name":42,"@type":43},"Stanford","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-30","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Which serum markers were evaluated for diagnosing liver cancers?","Question",{"text":63,"@type":64},"The study assessed AFP, AFP-L3%, and PIVKA-II, and also compared with CEA and CA19-9 across HCC, CCA, and benign liver disease cohorts.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were the diagnostic models and marker patterns evaluated?",{"text":68,"@type":64},"Clinical serum marker data were collected from 117 HCC, 28 CCA, and 101 benign cases, and the performance of published combined-marker models (e.g., GALAD, ASAP, GALAD-C, GAAP and related models) was analyzed for different diagnostic scopes and stages.",{"name":70,"@type":61,"acceptedAnswer":71},"What diagnostic models showed the highest efficacy and what did the authors conclude?",{"text":72,"@type":64},"For HCC, GAP-TALAD, GALAD, C-GALAD, ASAP and GALAD-C showed the highest efficacy; for overall liver cancers, GALAD-C, GAAP, GALAD, ASAP and C-GALAD; and for early liver cancers, GALAD, GALAD-C, GAAP, C-GALAD and ASAP. The authors concluded that combined-marker models improved diagnostic efficacy and some models can be prioritized in clinical practice.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},367695,1790251488,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":128,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},2336477552062,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","Submitted 25 September 2024 Accepted 16 June 2025  \nPublished 21 July 2025  \nCorresponding authors Xianghua Lin, [lxiangh@mail.sysu.edu.cn](lxiangh@mail.sysu.edu.cn)[ ](lxiangh@mail.sysu.edu.cn)Chaohui Duan, [duanchh@mail.sysu.edu.cn](duanchh@mail.sysu.edu.cn)  \nAcademic editor Vladimir Uversky  \nAdditional Information and Declarations can be found on page 16  \nDOI 10.7717/peerj.19712  \n Copyright 2025 Luo et al.  \nDistributed under  \nCreative Commons CC-BY 4.0  \nAnalysis of the optimal patterns of serum alpha fetoprotein (AFP), AFP-L3% and protein induced by vitamin K absence or antagonist-II (PIVKA-II) detection in the diagnosis of liver cancers  \nLing Luo*, Xiaochen Wang*, Xujian Peng, Runqiang Zhong, Xuejing Xuan, Haixiong Lin, Xianghua Lin and Chaohui Duan  \nDepartment of Clinical Laboratory, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China  \n* These authors contributed equally to this work.  \nABSTRACT  \nBackground: Liver cancers are common malignancies that primarily include hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA) . Currently, the most commonly used serum markers for HCC are alpha fetoprotein (AFP), AFP-L3% and protein induced by vitamin K absence or antagonist-II (PIVKA-II), while the most commonly used serum markers for CCA are carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9) . In recent years, many HCC diagnostic models using the combined detection of serum AFP, AFP-L3% and PIVKA-II have been established. For serum AFP, AFP-L3%, PIVKA-II and their many diagnostic models, there has been no clear guidance on the selection of these markers and their various combinations in the diagnosis of liver cancers. The aim of this study was to evaluate and compare the efﬁcacy of these markers and the models that incorporate them in diagnosing HCC and CCA. This could assist in identifying the optimal patterns of serum AFP, AFP-L3% and PIVKA-II for the diagnosis of liver cancers.  \nMethods: Clinical data and the results of serum AFP, AFP-L3%, PIVKA-II, CEA and CA19-9 were collected from 117 patients with HCC, 28 patients with CCA and 101 patients with benign liver diseases. Laboratory tests and detection of serum tumor markers in liver cancer patients were conducted prior to treatments. Recently published diagnostic models for AFP, AFP-L3% and PIVKA-II detection were collected; these included GALAD, ASAP, GALAD-C, GAAP, C-GALAD, C-GALAD II and GAP-TALAD.  \nResults: Levels of AFP-L3%, PIVKA-II, GALAD, ASAP, GALAD-C, GAAP,  \nC-GALAD and C-GALAD II signiﬁcantly differed between the patient cohorts, with the highest levels seen in HCC, followed by CCA and with the lowest levels seen in benign liver diseases (p \u003C 0.05) . Levels of CEA and CA19-9 signiﬁcantly differed between cohorts, with the highest levels seen in CCA, followed by HCC and with the lowest levels seen in benign liver diseases (p \u003C 0.05) . Levels ofAFP and GAP-TALADin HCC patients were signiﬁcantly higher than those in patients with CCA and patients with benign liver diseases (p \u003C 0.05), but there were no signiﬁcant differences in levels of AFP and GAP-TALAD between patients with CCA and benign liver  \nHow to cite this article Luo L, Wang X, Peng X, Zhong R, Xuan X, Lin H, Lin X, Duan C. 2025. Analysis of the optimal patterns of serum alpha fetoprotein (AFP), AFP-L3% and protein induced by vitamin K absence or antagonist-II (PIVKA-II) detection in the diagnosis of liver cancers. PeerJ 13:e19712 DOI 10.7717/peerj.19712  \ndiseases (p > 0.05) . In the diagnosis of HCC, GAP-TALAD, GALAD, C-GALAD, ASAP and GALAD-C showed the highest efﬁcacy. In the diagnosis of overall liver cancers (HCC and CCA), GALAD-C, GAAP, GALAD, ASAP and C-GALAD showed the highest efﬁcacy. In the diagnosis of early liver cancers (early HCC and CCA), GALAD, GALAD-C, GAAP, C-GALAD and ASAP showed the highest efﬁcacy.  \nConclusions: For serum AFP, AFP-L3% and PIVKA-II, diagnostic models of combined marker detection improved efﬁcacy in","cbCainx9WeuqhnxG","https://ap.wps.com/l/cbCainx9WeuqhnxG","pdf",1956244,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Introduction\n## Liver cancer burden and need for diagnosis\n## Role of tumor markers and AFP biology","[{\"question\":\"Which serum markers were evaluated for diagnosing liver cancers?\",\"answer\":\"The study assessed AFP, AFP-L3%, and PIVKA-II, and also compared with CEA and CA19-9 across HCC, CCA, and benign liver disease cohorts.\"},{\"question\":\"How were the diagnostic models and marker patterns evaluated?\",\"answer\":\"Clinical serum marker data were collected from 117 HCC, 28 CCA, and 101 benign cases, and the performance of published combined-marker models (e.g., GALAD, ASAP, GALAD-C, GAAP and related models) was analyzed for different diagnostic scopes and stages.\"},{\"question\":\"What diagnostic models showed the highest efficacy and what did the authors conclude?\",\"answer\":\"For HCC, GAP-TALAD, GALAD, C-GALAD, ASAP and GALAD-C showed the highest efficacy; for overall liver cancers, GALAD-C, GAAP, GALAD, ASAP and C-GALAD; and for early liver cancers, GALAD, GALAD-C, GAAP, C-GALAD and ASAP. The authors concluded that combined-marker models improved diagnostic efficacy and some models can be prioritized in clinical practice.\"}]","Analysis of the Optimal Patterns of Serum Alpha Fetoprotein (AFP), AFP-L3% and Protein Induced by Vitamin K Absence or Antagonist-II (PIVKA-II) Detection in the Diagnosis of Liver Cancers | PDF",1790172083,48,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/32ce1917c6cad3c0319da24822ae99d2.webp",983,1272,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0afb47bde88d45442403204ec54ef8d9.webp",982,1270,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3f94e7b5d885db44da8eb20df955a0e3.webp",981,1269,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6f0f53ca38451564bc862cb1f7a4af18.webp",980,1268]